found that decreased spexin levels were observed in T2DM patients and were further decreased in T2DM patients with cardiovascular disease (CVD) compared to the levels in controls, which indicated that spexin levels could serve as an early predictor of obesity-induced T2DM associated with CVD risk (16). The gene discussed is SPX; the disease is obesity disorder.